Digital biomarker for a low cost ambulatory test for early detection of alzheimer's disease
Active Project Grant Awarded Last action
- Award ID
- R01AG074204
- Recipient
-
University Of Texas Health Science Center At Houston UEI ZUFBNVZ587D4 Part of University Of Texas System
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,924,170
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 86% complete
- Originally
- Place of performance
- Houston, TX 77030, USA
Award details come from USAspending.gov.
Description
- Abstract
- Presently, no established biomarker exists to robustly predict the clinical manifestation of cognitive symptoms in persons with alzheimer's disease (ad) and ad-related dementias. Pet and MRI brain biomarkers are costly and invasive, thus there is a critical need for a noninvasive, inexpensive, and portable ad screening tool that can be easily deployed in-home or in residential communities. While non-brain signals characterizing biological and behavioral traits may prove valuable, two types of brain signal also hold strong promise as digital biomarkers of early stages of ad: epileptogenic activity (EA), and aberrant functional brain networks. Importantly, both biomarkers can be collected affordably and reliably with the latest dry-electrode ambulatory electroencephalography (EEG) technology. Ad patients have a tenfold higher seizure prevalence compared to the general population (pandis and scarmeas, 2012); however, the use of EA as an ad digital biomarker is largely unexplored. IT is also well known that amnestic MCI (amci) and ad patients show subtle functional network disruptions that are promising predictors of ad, as shown by our group (e.g pusil ET AL., 2019) and others, but there is no previous research assessing the joint impact between EA and functional networks. The scientific premise of this proposal is two-fold: (i) a combinatorial EA and functional network biomarker will predict conversion from amci to ad more robustly than a single signal in isolation, and (II) a novel deep learning model that performs multimodal (MEG and EEG) learning to find shared signatures of ad, but ultimately yields a model that needs affordable EEG-only data, will yield a powerful biomarker. This proposal will pursue three specific aims. 1) identify specific features of EA that prognosticate amci conversion; 2) design a digital biomarker that predicts amci conversion from EA features and functional brain networks; 3) extend the digital biomarker to ambulatory EEG with dry electrode technology. To achieve these aims, we will collect MEG, wet-electrode EEG, and dry-electrode (ambulatory) EEG data from 200 amci patients, evaluate their signals with expert epileptologists, and monitor the patient's yearly conversion rate to ad. We will then design and validate a deep learning model called siamese multiple graph to gauss (SMG2G), which performs multimodal learning on MEG and EEG network (graph) data but ultimately yields a model that needs EEG-only data to make predictions of amci conversion. The final product will be a dry-electrode ambulatory EEG digital biomarker that can be readily measured in home or in a residential facility. The research proposed in this application is innovative because IT is the first to combine EA and functional network signals to design an ad biomarker and achieves this by cutting- edge machine learning. IT is also significant because IT will advance the field vertically both scientifically and clinically by enabling large-scale, early detection of ad. Our team is especially well-prepared to undertake this project, with clinical and engineering expertise, strong collaboration over the years, with preliminary data supporting the aims, and institutional support.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $609,289 | |
| Amendment | $609,289 | |
| Amendment | $609,289 | |
| Amendment | $376,428 | |
| Amendment | $376,428 | |
| Amendment | $671,723 | |
| Original award | $671,723 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Massachusetts Institute Of Technology | $134,790 | |
| The University Of Texas Southwestern Medical Center | $161,660 | |
| Universidad Complutense De Madrid | $69,866 |
Quick answers
Who received award R01AG074204?
R01AG074204 was awarded to University Of Texas Health Science Center At Houston by National Institute on Aging (National Institutes of Health) on September 30, 2021.
How much is award R01AG074204 worth?
$3,924,170 has been obligated on R01AG074204.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award